Reckitt Benckiser to unveil £105 R&D site in Hull by end of June
pharmafile | April 11, 2019 | News story | Manufacturing and Production | Hull, R&D, Reckitt Benckiser, UK, pharma
Reckitt Benckiser (RB) has announced that its £105 million research and development facility in the UK city of Hull – the company’s largest-ever single investment – is to open before the end of June this year.
The new prospective date was set after the original unveiling, planned by the end of 2018, was postponed.
The site at Dansom Lane was touted as a major step in pushing UK to become a “world leader in science and innovation” as then-Chancellor George Osborne put it upon its original reveal in 2014.
“The main thing for us has been getting the quality right. These are health care products which we will be developing in the centre, so it is critical everything is correct,” commented Dr Bruce Charlesworth, Research and Development Site Lead at RB. “We are in the final stages, I think it is fair to say, and it is really just about putting the finishing touches on everything before we move in.”
Included within the site is a new laboratory suite and data procurement facilities, in addition to one of Europe’s largest stability testing suites.
“We have got to keep stock of the big products in all the shops, and previously when we have been doing testing there has been the risk of stocking problems,” Dr Charlesworth added. “The centre will also enable us to be more connected to our consumers. They will be able to see, touch and smell products in a way they haven’t been able to before.”
The investment marks the latest point in RB’s relationship with Hull, which began in 1840 when the company rented a starch mill in the city.
Matt Fellows
Related Content
Evotec and Dewpoint Therapeutics enter strategic partnership
Evotec and Dewpoint Therapeutics have announced a strategic R&D collaboration for the advancement of Dewpoint’s …
BMS shares new research and development plans at the company’s R&D day
Bristol Myers Squibb (BMS) recently held a Research and Development (R&D) Day in New York, …
FDA approves IMIDEX’s AI-powered device VisiRad XR
The technological pharmaceutical company IMIDEX has been granted clearance from the US Food and Drug …
